# FHND1002 for ALS Treatment: Phase 2

> **NCT07138014** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** FHND1002 100mg
- **DRUG:** FHND1002 200mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07138014
- **Lead sponsor:** Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07138014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07138014, "FHND1002 for ALS Treatment: Phase 2". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07138014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*